DPP4 and Hypoglycemia: Moreover, compared to AGIs, DPP4 inhibitors was associated with lower reductions of fasting blood glucose (WMD: -0.53 mmol/L, <i>P</i> < 0.001) and postprandial glucose at 2h (WMD: -0.60 mmol/L, <i>P</i> = 0.04), moderately increased body weight (WMD: 0.34 kg, <i>P</i> = 0.02), and decreased risk of gastrointestinal adverse events [risk ratio (RR): 0.48, <i>P</i> < 0.001], but unaffected risk of symptomatic hypoglycemia (RR: 0.96, <i>P</i> = 0.90).